Drug Profile
Anti-digoxin polyclonal antibody - AMAG Pharmaceuticals/Glenveigh Pharmaceuticals
Alternative Names: AMAG-423; Anti-digoxin-polyclonal-antibody-DigiFab; Anti-digoxin-polyclonal-antibody-DigiTAb; DIF; DigiBind; DigiFab; Digoxin Immune Fab; Digoxin Immune Fab (Ovine)Latest Information Update: 26 Sep 2022
Price :
$50
*
At a glance
- Originator Glenveigh Pharmaceuticals; Protherics
- Developer AMAG Pharmaceuticals; BTG Specialty Pharmaceuticals; Velo Bio
- Class Antidotes; Immunoglobulin fragments; Polyclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Poisoning
- No development reported Preeclampsia
Most Recent Events
- 26 Sep 2022 No development reported - Phase-II/III for Preeclampsia in Spain, USA, South Africa, United Kingdom, Poland (IV)
- 16 Nov 2020 AMAG Pharmaceuticals has been acquired by Covis Pharma
- 02 Sep 2020 AMAG Pharmaceuticals terminates a phase II/III trial in Preeclampsia in USA, United Kingdom, Spain, South Africa, Poland (due to futility reasons, as recommended by DSMB) (IV) (NCT03008616) (EudraCT2018-004212-21)